Live News • Aug 12
LB Pharmaceuticals Advances Phase 3 Schizophrenia Data Timeline and Raises $150 Million for Pipeline LB Pharmaceuticals reported that topline data from its pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia are now expected in the first half of 2027 and that it has closed a $150 million private placement to support operations and pipeline expansion.
The company plans to extend LB-102 into additional neuropsychiatric indications, using existing mechanistic, clinical and real-world evidence, and expects the new funding to support operations through multiple clinical milestones beyond Q2 2029.
LB Pharmaceuticals’ stock trades at $45.33, with the share price up 121.8% year to date.
The combination of an earlier Phase 3 data timeline and a larger cash runway gives LB Pharmaceuticals more flexibility to advance LB-102 across several indications, but it also concentrates future outcomes around clinical and regulatory events, particularly the NOVA-2 readout in 2027. Announcement • Jul 29
LB Pharmaceuticals Inc announced that it expects to receive $149.999899 million in funding from a group of investors LB Pharmaceuticals Inc entered into a Securities Purchase Agreement for a private placement to issue 3,577,560 shares at an issue price of $34.94 for the proceeds of $124,999,946.4 and 715,513 pre-funded warrants at an issue price of $34.9399 for the proceeds of $24,999,952.6687 for aggregate proceeds of $149,999,899.0687 on July 28, 2026.The financing includes participation from new and existing institutional investors, including Adage Capital Partners L.P managed by Adage Capital Management LP, BB Biotech, LLC, Caligan Partners LP, Commodore Capital, Deep Track Capital LP, funds managed by Farallon Capital Management LLC, Integral Health Asset Management LLC, Janus Henderson Investors, Spruce Street Capital LP, StemPoint Capital LP, a leading mutual fund and other investors. Each Pre-Funded Warrant has an initial exercise price per share of $0.0001, subject to certain adjustments. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire. The Private Placement is expected to close on or about July 30, 2026, subject to the satisfaction of customary closing conditions. The Company has agreed to pay the placement agents customary placement fees in their capacity as placement agents for the sale of the Securities to the Investors. The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each of the Investors has provided representations appropriate for a private placement of securities. The sale of the Shares did not involve a public offering and was made without general solicitation or general advertising. Announcement • Jul 22
LB Pharmaceuticals Inc Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia LB Pharmaceuticals Inc. issued a press release announcing accelerated timing of topline results from the Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia. Based on enrollment projections, it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in the first half of 2027 and to schedule a pre-NDA meeting with the FDA thereafter in the second half of 2027. NOVA-2 is a pivotal Phase 3 multi-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of LB-102 for the treatment of schizophrenia. The trial is designed to enroll approximately 460 patients across 25 sites in the U.S. Enrollment in the pivotal Phase 3 NOVA-2 trial has been more rapid than expected. Based on the pace of enrollment since initiating NOVA-2, topline results are expected in the first half of 2027, ahead of prior guidance of the second half of 2027, and a pre-NDA meeting is to be scheduled soon thereafter in the second half of 2027. The company remains well capitalized with a cash runway expected to fund operations into the second quarter of 2029 through multiple clinical readouts, with topline data from the Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar depression expected in the first quarter of 2028, and from the Phase 2 trial of LB-102 in adjunctive MDD in the first half of 2029. LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the United States for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotic outside the United States, LB-102 was developed to retain amisulpride's benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5HT-7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. In this trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside effects on negative symptoms and cognitive performance. The pivotal Phase 3 NOVA-2 trial of LB-102 for acute schizophrenia and the Phase 2 ILLUMINATE-1 trial of LB-102 for bipolar 1 depression are ongoing, and a Phase 2 trial of LB-102 in adjunctive treatment of MDD is planned. Additional expansion opportunities for LB-102 include predominantly negative symptoms of schizophrenia, Alzheimer's disease psychosis and agitation, as well as other neuropsychiatric diseases. 
